PHVS - Latest News

Pharvaris N.V. (PHVS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $2.46B. Beta to the broader market is -2.33.

The article list below shows the most recent PHVS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PHVS Headlines

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

globenewswire.com - Aug 12, 2026

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykini

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

globenewswire.com - Aug 6, 2026

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykini

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

seekingalpha.com - Aug 4, 2026

Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) for

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

zacks.com - Jul 31, 2026

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hard

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

fool.com - Jul 24, 2026

This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.

How News Affects PHVS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PHVS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PHVS news questions

What is the latest PHVS news headline?

The most recent PHVS headline (Aug 12, 2026) is "Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PHVS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PHVS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PHVS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.